B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14

Theravance Biopharma, Inc. (NASDAQ:TBPH) is one of the most undervalued biotech stocks to buy right now. B. Riley lifted the price target on Theravance Biopharma, Inc. (NASDAQ:TBPH) to $17 from $14 on April 7, reiterating a Neutral rating on the shares. The firm told investors that the final generic settlement with MannKind Corporation locks exclusivity through April 2039, “removing the last overhang on a clean single-asset story”.

In its financial and operational results for fiscal Q4 and full year 2025, Theravance Biopharma, Inc. (NASDAQ:TBPH) stated that the company ended the year “on a positive note from a financial perspective”, attaining “another record quarter of non-GAAP profitability, hitting a new all-time high for YUPELRI® brand-level profitability, and reaching $75 million in key sales-based milestones.” Management stated that the results highlight the durability and strength of the company’s commercial asset, YUPELRI®, as well as the strength of its balance sheet. Theravance Biopharma, Inc. (NASDAQ:TBPH) also reported that the full-year 2025 TRELEGY net sales, reported by GSK, were $3.9 billion, up 12% year-over-year, which triggered a $50 million milestone payment.

Theravance Biopharma, Inc. (NASDAQ:TBPH) is a biopharmaceutical company involved in the discovery, research, development, and commercialization of respiratory medicines. The company’s operations are divided into the following geographical segments: the U.S. and Europe.

While we acknowledge the risk and potential of TBPH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TBPH and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.